Fate Therapeutics (FATE) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
12th Annual Cantor Fitzgerald Global Healthcare Conference summary
9 Sep, 2026Strategic vision and manufacturing innovation
Master cell bank enables production of over 10 million doses per bank and 50,000 doses per batch, ensuring uniformity, reliability, and cost-effectiveness at ~$3,000 per dose.
Manufacturing process allows for rapid, on-demand treatment, reducing patient burden and risk associated with traditional CAR T manufacturing delays.
Uniform product quality eliminates variability seen in autologous and allogeneic CAR T therapies, supporting consistent clinical outcomes.
Off-the-shelf inventory model positions the company to serve large patient populations and underserved regions.
Next 12 months anticipated as a pivotal period with significant milestones and data updates.
Clinical program highlights and safety profile
FT819, the lead program, is designed for safety at molecular, manufacturing, and clinical levels, with controlled CAR expansion and no TCR expression to prevent GvHD.
Over 30 autoimmune and 50 oncology patients have been dosed with a favorable safety profile and limited adverse events.
Less intensive or no conditioning regimens are used, reducing risks of cytopenia and infection, and supporting outpatient administration.
Potency demonstrated by efficacy without intensive conditioning; persistence in blood not correlated with long-term outcomes, but early activity is key.
Phase II trial design and regulatory engagement
Phase II lupus nephritis trial is open-label, single-arm, targeting 53 patients, with primary endpoint of complete renal response (CRR) at six months.
Historical control for CRR is 10%-20%, with the program aiming for a 30%-40% response rate.
Single-dose treatment shows significant UPCR reductions and quality of life improvements, supporting potential for accelerated approval.
Enrollment expected to complete in 18 months, with interim analysis planned for the second half of next year and study completion in 2028.
Regulatory relationship is strong, with ongoing discussions and alignment on trial design and endpoints.
Latest events from Fate Therapeutics
- FT819 advances off-the-shelf CAR T into lupus nephritis and broader autoimmune care.FATE
Jefferies Global Healthcare Conference - $100 million Leerink ATM adds financing flexibility but carries material dilution risk.FATE
Registration filing - RECLAIM-LN advanced as management’s grant-inclusive runway outlook extended to mid-2028.FATE
Q3 2026 - Net loss narrowed, cash runway into 2028, and pivotal CAR T-cell trials advanced.FATE
Q2 2026 - Early lupus trial data with flexible CAR T protocols expected by year-end, focusing on B-cell reset.FATE
Jefferies 2024 Global Healthcare Conference - FT819 and next-gen CAR T-cell therapies show strong clinical progress and financial stability.FATE
Corporate presentation - Net loss narrowed on lower expenses, with strong cash and key CAR T-cell advances, but risks remain.FATE
Q1 2026 - Key votes include director elections, auditor ratification, and incentive plan amendment.FATE
Proxy filing - Shareholders will vote on director elections, auditor ratification, say-on-pay, and equity plan expansion.FATE
Proxy filing